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http://dx.doi.org/10.1016/j.celrep.2016.05.063SUMMARY
Current treatment regimens for pancreatic ductal
adenocarcinoma (PDAC) yield poor 5-year survival,
emphasizing the critical need to identify druggable
targets essential for PDAC maintenance. We devel-
oped an unbiased and in vivo target discovery
approach to identify molecular vulnerabilities in
low-passage and patient-derived PDAC xenografts
or genetically engineered mousemodel-derived allo-
grafts. Focusing on epigenetic regulators, we identi-
fied WDR5, a core member of the COMPASS histone
H3 Lys4 (H3K4) MLL (1–4) methyltransferase com-
plex, as a top tumor maintenance hit required across
multiple human and mouse tumors. Mechanistically,
WDR5 functions to sustain proper execution of DNA
replication in PDAC cells, as previously suggested by
replication stress studies involvingMLL1, and c-Myc,
also found to interact withWDR5.We indeed demon-
strate that interaction with c-Myc is critical for this
function. By showing that ATR inhibition mimicked
the effects of WDR5 suppression, these data provide
rationale to test ATR and WDR5 inhibitors for activity
in this disease.This is an open access article under the CC BY-NINTRODUCTION
The incidence of pancreatic ductal adenocarcinoma (PDAC) is
rising across the world, and the disease is associated with a
very high mortality rate: 75% of patients die within the first year
of diagnosis and only 7% survive longer than 5 years (American
Cancer Society, 2015). The clinical management of PDAC de-
pends on the stage of the disease. Only about 15% of PDAC
cases are diagnosed early enough to undergo surgical resection
followed by adjuvant therapy (Stathis and Moore, 2010). For pa-
tients who are not candidates for surgery, two drugs, gemcita-
bine and erlotinib, were first approved for PDAC treatment by
the US FDA, with two novel regimens approved in recent years,
FOLFIRINOX and nab-paclitaxel (Conroy et al., 2011; Von Hoff
et al., 2013). However, the impact of chemo-radiotherapy is often
transient and produces modest survival benefit.
The majority of pancreatic adenocarcinomas harbor mutant
KRAS, which plays a key role in reprogramming pancreatic
cancer cells into duct-like lineages capable of progressing
from pre-neoplastic lesions to advanced PDAC, as demon-
strated in genetically engineered mouse models (GEMMs) (Al-
moguera et al., 1988). PDAC progression is accompanied by
genomic deletion and/or loss-of-function mutations in tumor
suppressor genes (TSGs), including TP53, CDKN2A, SMAD4,
and PTEN (Hingorani et al., 2003, 2005). Recent large-scale
genome profiling of human PDAC has revealed mutationalCell Reports 16, 133–147, June 28, 2016 ª 2016 The Authors. 133
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
events contributing to epigenetic deregulation, as the loss-of-
function somatic mutations in three members of the chromatin-
modifying COMPASS-like complex family, MLL3, MLL4, and
UTX, at a cumulative frequency exceeding 20% of cases (Bian-
kin et al., 2012, Waddell et al., 2015). All COMPASS-like com-
plexes share the core WRAD (WDR5-RBBP5-ASH2L-DPY30)
components but assemble selectively with different MLL pro-
teins (MLL1–4), which possess a common H3K4 methyltransfer-
ase (MT) activity due to a conserved SET domain, resulting in
‘‘activating’’ marks on chromatin at actively transcribed regions
(Trievel and Shilatifard, 2009; Smith et al., 2011). Despite this
common function, COMPASS-like complexes have a range of
both redundant and non-redundant roles, including methyl-
ation-independent roles, in cell development, cell cycle, and dif-
ferentiation (Smith et al., 2011).
The lack of effective treatment regimens in PDAC has moti-
vated us to conduct a systematic functional approach to target
identification, with the goal of identifying druggable epigenetic
components. Pooled short hairpin RNA (shRNA) libraries have
been exploited to identify in vitro synthetic lethal interactions
and targetable genetic dependencies in cancer cell lines (Moffat
et al., 2006; Schlabach et al., 2008; Silva et al., 2008; Scholl
et al., 2009; Hoffman et al., 2014). Adaptation of these ap-
proaches to in vivo screens, predominantly focused on the
identification of TSGs in mouse models, expanded our ability
to capture more of the cancer biological complexity (Zender
et al., 2008; Meacham et al., 2009). Following on recent in vivo
screens with human cancer cell lines enforced the importance
of capturing the role of key genetic elements in the hallmarks
of cancer, including complex heterotypic cancer-host interac-
tions but were limited in their broad application by the inability
to efficiently evaluate the xenotransplantation potentials (Posse-
mato et al., 2011; Possik et al., 2014; Baratta et al., 2015). Here,
we developed PILOT (Patient-Based In Vivo Lethality to Opti-
mize Treatment), an in vivo platform that enables the identifica-
tion of oncogenic drivers necessary for tumor maintenance
in patient-derived xenografts. This is particularly important given
the paucity of novel, and most importantly, truly validated
oncology drug discovery targets.
RESULTS
Development of an In Vivo Functional Genomic Screen in
Patient-Derived Xenografts
We first established a rapid and reproducible protocol to isolate
primary tumor cells from patient-derived xenograft (PDx) tissue
or genetically engineered mouse models (GEMMs). These pri-
mary models more closely reflect the histologic and phenotypic
complexity of human tumors. More importantly, short-term
cultures isolated from primary models recapitulate the complex
histology of human PDAC (i.e., glandular structures surrounded
by dense desmoplasia) when implanted into immunocompro-
mised mice (Figures 1A, S1A, and S1B; Table S1). In vivo shRNA
screens rely on the specific elimination of individual shRNAs in a
cell population and require therefore that the infected cell popu-
lation be adequately endowed with tumor engraftment capacity
when implanted into recipient mice. The ability of a tumor cell
population to engraft and propagate itself when implanted in vivo134 Cell Reports 16, 133–147, June 28, 2016varies dramatically among tumor types and must be accurately
determined to ensure faithful representation of complex, pooled
shRNA libraries (Quintana et al., 2008; Ishizawa et al., 2010).
Most commonly, the engraftment efficiency is a measure of the
tumor-initiating cell (TIC) frequency, and it is assessed by in vivo
transplantation upon extreme limiting dilution assays (Hu and
Smyth, 2009; Bonnefoix and Callanan, 2010), but this approach
is time consuming and results are widely variable across biolog-
ical replicates. This limits the use of biologically relevant PDx
models, as low-passage human cells have a very low and vari-
able TIC frequency relative to established human and murine
cell lines. To rapidly and accurately determine the engraftment
efficiency required by each PDAC model, we used a non-target-
ing ‘‘tracking’’ library expressing 12,500 unique molecular barc-
odes in early passage tumor samples to ‘‘tag’’ individual cells
and assess their fate by comparing clone representation in in-
fected cells with that emerging after tumor establishment in
recipient mice (Figure 1B).
To demonstrate the power of the approach, we infected cells
isolated from early passage human PDAC xenografts (MDA-
PATX43, MDA-PATX50, MDA-PATX53, MDA-PATX66) and
PDAC GEMM-derived allografts (Ptf1a-Cre, KrasG12D_LSL/+,
Tp53L/L; Ptf1a-Cre, KrasG12D_LSL/+, Cdkn2aL/L; Ptf1a-Cre,
KrasG12D_LSL/+ escaper line), which displayed either epithelial
or mesenchymal histological features (Figure S1B), with the
tracking library at a low MOI (less than one integrant/cell) (Fig-
ure S1C; Table S2) and implanted infected cells (puromycin se-
lection) subcutaneously into NSGmice. To model optimal library
distribution, we analyzed tumors seeded with 80, 240, or 400 in-
dividual cells/barcode (Figures 1C, S1D, and S1E). Tumors were
isolated from mice, and individual barcodes were quantified by
deep sequencing for comparison with the reference cell popula-
tion. As anticipated, implantation of fewer cells/barcode was
required to adequately represent the tracking library (refer-
ence/tumor Log2 ratio resulted in a normal distribution) in murine
cells (80 cells/barcode) compared to all four PDx cell populations
(Figures 1D, S1F, and S1G). We also observed variability
among PDx derived samples, demonstrating coverage of the
tracking library with implantation of 400 cells/barcode in MDA-
PATX53 and MDA-PATX43 (Figures 1E and S1H), but not in
MDA-PATX50 and MDA-PATX66 even with implantation of 400
cells/barcode, suggesting the engraftment efficiency in these
cell lines was too low to sustain the expression of a library of
such complexity (Figures 1F and S1H). Assessment of TIC fre-
quency by extreme limiting dilution was supportive of our con-
clusions from the tracking library (Figure 1G). Thus, our approach
facilitates rapid assessment of xenotransplantation potential in
order to optimize experimental design and ensure adequate li-
brary complexity, vastly elevating the utility of excised tumor
samples for genetic screen approaches.
In Vivo Loss-of-Function Screens to Identify Epigenetic
Vulnerabilities in Patient-Derived Xenografts and
Mouse Models of PDAC
To explore the utility of our system in the discovery of therapeutic
targets, we focused on an extensive collection of chromatin reg-
ulators in the context of PDAC. Genetic lesions in chromatin reg-
ulators have been identified in a variety of cancers, and new
BC D
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Figure 1. Determination of Engraftment Efficiency Using a Molecular Barcoded-Lentiviral Library
(A) Histological sections of PDAC patients (patient 53, patient 43, 103) were stained with H&E and compared with the sections collected from the matched PDx
models (MDA-PATX53, MDA-PATX43). Xenografts (I–II) were stained for Cytokeratin 19 and Vimentin (103). Bright field of stabilized cells (203).
(B) Outline of experimental design for in vivo engraftment efficiency study in xenografts and mouse models of PDAC (MOI; Ref Cells, infected and selected cells
before injection; Barcode, 18 unique nucleotides), representative analysis of cells infectedwith a pool of molecular barcodes (18 nucleotides) (i, model for covered
complexity; ii, model for not-covered complexity).
(C) Density plot of the Tumor/Ref Log2 ratio (median between triplicates) for the xenograft-derived MDA-PATX53 cells infected with the 12.5k barcoded library at
increased coverage: 80, 240, and 400 cells/barcode.
(D) Density plot for the Tumor/Ref Log2 ratio (median between replicates) from the Ptf1a-Cre, Kras
G12D_LSL/+, Tp53L/L (KP53) cells infected with the 12.5k bar-
coded library with a coverage of 80 cells/barcode;
(E and F) Density plot of the Tumor/Ref ratio (median between replicates) for the xenograft-derived MDA-PATX43, MDA-PATX50, MDA-PATX53, and MDA-
PATX66 cells infected with the 12.5k barcoded library with a coverage of 400 cells/barcode.
(G) Extreme limiting dilution analysis (ELDA) of PDAC GEMM-derived cells and human PDx cells.
See also Figure S1 and Tables S1 and S2.epigenetic cancer dependencies are emerging as actionable vul-
nerabilities (Dawson and Kouzarides, 2012; Hoffman et al.,
2014). More specifically, epigenetic deregulation is a docu-
mented genetic hallmark of PDAC and developmental oncobiol-
ogy overall, implying a causal role in disease pathogenesis
(Omura and Goggins, 2009). To probe epigenetic vulnerabilities
in PDAC, and guided by the engraftment efficiency results from
our tracking library, we enlisted three murine cell lines and
MDA-PATX53 and MDA-PATX43 in in vivo screens of an shRNAlibrary targeting 236 unique mouse or human epigenetic regula-
tors (Figures 2A, S2A, and S2B). To enhance the robustness of
the screen and facilitate hit prioritization, the library was de-
signed with ten unique shRNAs targeting each epigene. To
ensure adequate representation of the complexity of our deep-
coverage epigenetics library in human and mouse samples,
mice were implanted respectively with 2,000 cells/shRNA and
400 cells/shRNA, and barcode abundance was quantified in es-
tablished xenografts by deep sequencing (Figures 2B, 2C, S2C,Cell Reports 16, 133–147, June 28, 2016 135
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and S2D). Comparison among replicates (Pearson’s correlation
factor) confirmed the usefulness of our tracking approach in pre-
dicting the engraftment efficiency (Figure S2E).
To detect the top 15%–30% most-depleted shRNAs we
applied a cumulative distribution function (CDF) as a first-line
filter, using thresholds of 2/-4 Log2 (Figure 2D). Imposing
the same thresholds on the previously introduced engraftment
efficiency study with the tracking library (see above), we
observed less than 2.5% barcode scoring, substantiating that
we were only detecting significantly depleted hairpins (Fig-
ure 2E). Multiple methods were leveraged to evaluate ‘‘hits’’
(or top-scoring genes) emerging from our screens, including
mean of the top-scoring three hairpins and p values from
RSA (or redundant shRNA activity) scores (Figure 2F). Notably,
irrespective of the used approach, two well-known essential
genes encoding for a proteasome (PSMA1) and a ribosomal
(RLP30) protein added to the library as positive controls scored
among the most-depleted hits (Figure 2F), as did PHF5A,
SMC2, and BRD4, all known to have a role in cancer (Hubert
et al., 2013; Krattenmacher et al., 2014; Sahai et al., 2014).
Unsupervised clustering analysis of all genes in the library vali-
dated replicates across tumors but also identified vulnerabil-
ities unique to each model (Figure S3). Downregulation of
PHF5A, SMC2, and WDR5 using two independent singleton
shRNAs significantly impaired new colony formation and tumor
growth in both human (Figure 2G) and mouse PDAC models
(Figures 2H and S2F).
WDR5 Is Essential for PDAC Initiation and Proliferation
One of the most robust hits to emerge across multiple screens
was theWD repeat-containing protein 5 (WDR5), a core member
of the COMPASS histone H3 Lys4 (H3K4) methyltransferase
complex (Steward et al., 2006; Trievel and Shilatifard, 2009;
Smith et al., 2011). Recently, WDR5 upregulation was detected
in prostate and bladder cancers, where it was also found to be
critical for cancer cell proliferation (Kim et al., 2014; Chen
et al., 2015). We first confirmed deregulated expression of
WDR5 in human PDAC compared to normal control pancreas
(Figure 3A). WDR5 knockdown dramatically affected tumor
growth of orthotopically implanted patient-derived PDAC cells
and extended survival compared to non-targeting (NT) shRNA
controls (Figure 3B). The observed effects were confirmed to
be on target, as expression of ectopic WDR5 cDNA lacking theFigure 2. In Vivo shRNA Screens of Epigenetic Vulnerabilities in Patien
(A) Outline of experimental design for deep-coverage shRNA screens in xenografts
injection; Barcode, 18 unique nucleotides).
(B) MDA-PATX53 cells were screened in triplicate with a coverage of 2,000 cells
(C) Ptf1a-Cre, KrasG12D_LSL/+, Tp53L/L (KP53) cells were screened in triplicate wit
(D) Cumulative distribution function (CDF) of shRNA’s fold change (Tumor/Ref L
Tp53L/L (KP53) mouse model (right panel).
(E) Overlapped Tumor/Ref ratios (Log2 ratio) of the engraftment efficiency studies
Cre, KrasG12D_LSL/+, Tp53L/L (KP53) (right panel), Log2 ratio values corresponding
graphs (dashed gray lines).
(F) Heatmap of the top-scoring hits generated applying a p value-based cutoff
shRNAs), Ranking determined applying the mean Z score. Negative controls (Lu
(G and H) Western blot, xenotransplantation tumor size (mm3) and colony forma
Tp53L/L (KP53) cells infected with two independent shRNAs against the top-scori
See also Figures S2 and S3.30 UTR targeted by the shRNA rescued the impairment in colony
formation ability upon WDR5 knockdown (Figures 3C and S4A).
Next, we confirmed an essential role across multiple primary pa-
tient-derived PDAC in vivo models (Figures 3D and S4B). More-
over, we also generated pancreatic cancer spheres from both
human and mouse PDAC samples using serum-free 3D growth
conditions (Viale et al., 2014). Consistent with the observed
in vivo response, WDR5 knockdown significantly impaired the
spherogenic potential of these tumor-initiating cells, as demon-
strated by calcein staining and spheroid counts (Figures S4C
and S4D).
To evaluate whetherWDR5was essential for proliferation of an
established PDAC tumor, we infected patient-derived cells
(MDA-PATX53 and MDA-PATX66) with Tet-inducible WDR5
shRNA (Sh1 hWDR5i, Sh2 hWDR5i) or control shRNA constructs
(Sh NTi) and transplanted them in host mice (n = 5) (Figure S4E).
We observed a dramatic growth arrest of established tumors
upon WDR5 downregulation under doxycycline treatment that
was maintained through the end of the study (Student’s t test,
p < 0.05) (Figures 3E, 3F, and S4F). Immunohistochemistry stain-
ing confirmed that WDR5 knockdown was positively correlated
with a robust reduction of the proliferation marker Ki67 (Fig-
ure 3G). Taken together, these data confirm that WDR5 is a crit-
ical regulator of tumor growth in human PDAC.
WDR5 Inhibition Arrests Tumor Progression of
Autochthonous PDAC Models
To further validate the biological role of WDR5 in tumor mainte-
nance, we developed an autochthonous lentiviral-based so-
matic-mosaic (pLSM5) in vivo system. We designed a modular
system by combining the Cre-LoxP and Flpo-Frt technologies
in a single vector, thereby generating PDAC cells carrying a
latent shRNA to allow time-restricted, acute inactivation of
any gene of interest in established tumors generated from
cells transplanted in the pancreas of host recipients (Fig-
ure 4A). Specifically, early epithelial progenitor cultures were
established from R26Cag-FlpoERT2/+; KRasG12D_LSL/+; Tp53L/L or
Rosa26mTmG/+ embryonic livers and expanded ex vivo (Zender
et al., 2008). Cells were transduced with the pLSM5 system
where a Frt-stop-Frt cassette containing the Cre recombinase
under the Krt19 promoter was cloned between the U6 promoter
and the shRNA and transplanted in immunocompromised
Rag2/mice pretreated with cerulein (Figure S5A). Specifically,t-Derived and Mouse Models of PDAC
andmousemodels of PDAC (MOI; Ref Cells, infected and selected cells before
/shRNA (Tumor/Ref Log2 ratio).
h a coverage of 400 cells/shRNA (Tumor/Ref Log2 ratio).
og2 ratio) for human MDA-PATX53 (left panel) and Ptf1a-Cre, Kras
G12D_LSL/+,
and the corresponding shRNA screens in MDA-PATX53 (left panel) and Ptf1a-
to the ±2 SDs in the engraftment coverage (TIC) studies are highlighted in the
(p < 0.05) associated with the Z score (fold change, average of the top three
c1–4), positive controls (Psma1, Rpl30, Pcna).
tion assay for the human MDA-PATX53 and mouse Ptf1a-Cre, KrasG12D_LSL/+,
ng hits: WDR5, PHF5A, and SMC2 (h, human; m, mouse). Data are mean ± SD.
Cell Reports 16, 133–147, June 28, 2016 137
050
100
150
200
250
Normal Pancreas 
 (42) 
PDAC  
(60) 
p<0.005 
IH
C
 In
te
ns
ity
 
40 45 50 55 60 65 70 75 80 85 90 95
0
250
500
750
1000
1250
1500
Days 
T
u
m
o
r 
V
o
lu
m
e
 (
m
m
3
)
+ DOX 
sh NTi
sh1 hWDR5i
sh2 hWDR5i
MDA-PATX80 
p<0.005 p<0.005 
15 20 25 30 35 40 45
0
250
500
750
1000
1250
1500
Days 
T
u
m
o
r 
V
o
lu
m
e
 (
m
m
3
)
+ DOX 
sh NTi
sh1 hWDR5i
sh2 hWDR5i
sh
NT
sh
1 h
W
dr
5
sh
2 h
W
dr
5
0
200
400
600
800
m
m
3
MDA-PATX92 
p<0.005 p<0.005 
0 20 40 60 80
0
50
100
Days 
P
e
rc
e
n
t 
s
u
rv
iv
a
l
B 
Sh NT Sh1 hWDR5 Sh2 hWDR5 
D 
Sh NT
Sh1 hWDR5
Sh2 hWDR5
A 
PD
AC
  
N
orm
al Pancreas 
C 
WDR5 
-Actin 
+ + 
+ + - - 
- - WDR5_IRES_GFP 
GFP_IRES_GFP 
GFP 
ShNT Sh1 hWDR5 
G
FP
 
W
D
R
5 
MDA-PATX53 
sh
NT
sh
1 h
W
dr
5
sh
2 h
W
dr
5
0
200
400
600
800
m
m
3
MDA-PATX77 
p<0.005 p<0.005 
E F 
MDA-PATX66 
G 
sh
1 
hW
D
R
5i
 
sh
 N
Ti
 
Wdr5 
Wdr5 
Ki67 
Ki67 
MDA-PATX53 
Figure 3. WDR5 Is Essential for PDAC Initiation and Proliferation
(A) Boxplot of WDR5 intensity staining (0–300, percentage of positive cells by intensity) in pancreatic ductal adenocarcinoma TissueMicro-Array (102 cases total,
42 normal pancreas, 60 PDACs, Student’s t test p < 0.005).
(B) Non-invasive bioluminescence imaging (day 30) of representative mice injected with MDA-PATX53 cells expressing shRNA targeting WDR5 (Sh1 hWDR5 and
Sh2 hWDR5) and control (Sh NT); percentage survival (n = 5, Student’s t test p < 0.004).
(C) Colony formation assay (CFA) of MDA-PATX53 cells expressing pHAGE-GFP_IRES_GFP or pHAGE-WDR5_IRES_GFP and shRNA targeting WDR5
(sh1_WDR5) or control (sh_NT); Protein expression of WDR5, GFP, and b-actin.
(D) Tumormeasurement (mm3) of three primary PDAC xenograft-derived cells (MDA-PATX77, MDA-PATX80, MDA-PATX92) expressing shRNAs targetingWDR5
(sh1 hWDR5, sh2 hWDR5) and control (sh NT); median (n = 5, Student’s t test p < 0.005).
(E and F) Tumor-growth curve (mm3) of xenograft-derivedMDA-PATX53 andMDA-PATX66 cells carrying Tet-ON inducible WDR5 shRNAs (Sh1 hWDR5i and Sh2
hWDR5i) or control (sh NTi) (n = 5, Student’s t test p < 0.03). Size measurements were performed every 5 days. Mice were subjected to doxycycline-containing
drinking water regimen from day 20 (MDA-PATX53) or day 55 (MDA-PATX66) until the end of the study.
(G) Immunohistochemistry staining (Wdr5, Ki67, 103) of tumors generated transplanting MDA-PATX53 cells carrying Tet-ON inducible WDR5 shRNA (Sh1
hWDR5i) or control (sh NTi). Mice were sacrificed 72 hr after doxycycline supplementation in the drinking water. Data are mean ± SD.
See also Figure S4.transplanting epithelial progenitors from Rosa26mTmG/+ mice,
upon infection with the pLSM5-K19 lentiviral vector, we
observed no tumor formation and differentiation in pancreatic
acini, as demonstrated by double positivity for GFP and amylase
of pancreatic sections (Figures 4B and S5B), suggesting that
early embryonic liver progenitors can be reprogrammed by the
host microenvironment toward a pancreatic exocrine differentia-
tion. Instead, R26Cag-FlpoERT2/+; KRasG12D_LSL/+; Tp53L/L trans-
plants generated tumors and expressed the epithelial markers138 Cell Reports 16, 133–147, June 28, 2016Cytokeratin 19 and Sox9 and the pancreas-specific marker
PDX1, suggesting that embryonic endodermal progenitors are
remarkably adaptable and able to generate pancreatic tumors,
which pathologically recapitulate the human counterpart (Fig-
ures 4C, S5C, and S5D). Upon tumor establishment, FlpoERT2
was activated by repeated tamoxifen (Tx) treatments to remove
the stopper cassette and activate the shRNA (Figure 4D).
Consistent with the above findings, acute inactivation of Wdr5
in vivo resulted in a dramatic increase of overall survival and
shNT + Tx
0 2 0 4 0 6 0
0
5 0
1 0 0
T x (D 5 )
shNT + Veh
Amylase DAPI GFP 
Rosa26mTmG/+; pLSM5-K19
Amylase DAPI GFP 
Rosa26Cag-FlpoERT2
KRasG12D_LSL/+ 
Tp53L/L 
      or 
Rosa26mTmG/+ 
 E13 Embryos 
epithelial liver 
progenitors 
pancreatic tail 
injection 
pLSM5-K19-shRNA (Flpo-OFF) 
A 
T
x
V
eh
Wdr5 
Wdr5 
Ki67 
Ki67 
Rosa26Cag-FlpoERT2; KRasG12D_LSL/+; Tp53L/L; pLSM5-K19-shWdr5 
B 
H 
Rosa26Cag-FlpoERT2; KRasG12D_LSL/+; Tp53L/L; pLSM5-K19
H&E Cytokeratin 19 
PDX1 SOX9 
C 
D 
n.s.
shWdr5 + Veh
shWdr5 + Tx
P
er
ce
nt
 S
ur
vi
va
l
Days
G 
T1 (+8 days)T0
V
eh
T
x
Transplant
MRI T0 (d8) MRI T1 (d16)
Treatment
0
100
200
300
400
0
500
1000
1500
2000
2500
T0 T1
T0 T1
Vehicle
Tamoxifen (Tx)
V
ol
um
e 
(m
m
3 )
V
ol
um
e 
(m
m
3 )
p<0.5
p<0.05
Rosa26Cag-FlpoERT2; KRasG12D_LSL/+; Tp53L/L; pLSM5-K19-shWdr5 
E 
Tu
m
or
 w
ei
gh
t (
gr
) 
p<0.005 
0
2
4
6
8
Tx Veh
F 
p<0.0005
Figure 4. WDR5 Inhibition Arrests Tumor Progression of Autochthonous PDAC Models
(A) PDAC somatic mouse model experimental scheme (E13, embryonic day 13); specifically, early epithelial progenitor cultures were established from
KRasG12D_LSL/+; Tp53L/L; R26Cag-FlpoERT2/+ or Rosa26mTmG/+ embryonic livers and expanded ex vivo. Cells were transduced with the pLSM5 system and
transplanted orthotopically in immunocompromised Rag2/ mice.
(B) Immunofluorescence staining (Amylase, GFP, DAPI, Merge, 203; highlighted areas, 603) of normal pancreas collected from recipient mice transplanted with
Rosa26mTmG/+ epithelial progenitors upon infection with pLSM5-K19 (no shRNA).
(C) Immunohistochemistry staining (H&E, Cytokeratin 19, PDX1, Sox9, 203) of tumors harvested from somatic models in the KRasG12DLSL/+; Tp53L/L;
R26Cag-FlpoERT2/+ background infected with pLSM5-K19 (no shRNA).
(D) Representative MRI sections of mice transplanted with KRasG12DLSL/+; Tp53L/L; R26Cag-FlpoERT2/+; pLSM5-K19-shWdr5 cells randomized to vehicle (Veh) or
tamoxifen (Tx) treatment. Mice were imaged at days 8 and 16 (n = 4/group). Treatment was started at day 8.
(E) Dot plots showing the individual tumor volumes at T0 and T1 time points for vehicle (ANOVA test p < 0.05) or tamoxifen (ANOVA test p < 0.5)-treated mice.
(legend continued on next page)
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inhibition of tumor growth (Figures 4D–4G), characterized by a
decrease in the numbers of Ki67 positive cells and accumulation
of DNA damage (gH2AX staining) (Figure 4H).
The COMPASS Complex Is a Critical Regulator of PDAC
Development
COMPASS and COMPASS-like complexes are characterized
by their unique subunit composition, and individual subunits
appear to dictate the biological functions of each complex
(Trievel and Shilatifard, 2009; Smith et al., 2011). For example,
even though both MLL1 and MLL2 are recruited to the Hox loci
through MEN1-specific interactions, they also have non-redun-
dant functions, as exemplified by the phenotypes of MLL1 and
MLL2 knockout mouse models (Yu et al., 1995; Wang et al.,
2009). The WDR5-RBBP5-ASH2L (WAR) core showed high
protein expression level in human PDAC xenografts, associated
with a hypermethylation phenotype (Figure 5A). The functional
non-redundant role of the COMPASS complex in human
PDAC was proved by the significant impairment of colony for-
mation ability we observed when ASH2L, RBBP5, and MLL1
were downregulated in PDX-derived samples using two
independent shRNAs (Figures 5B–5E and S6A–S6D). In addi-
tion, the downregulation of each member of the so-called
WAR module (WDR5-ASH2L-RBBP5) in human PDAC models
affected the expression of a set of common genes highlighting
a critical role of the complex in sustaining tumor proliferation
(Figure S6E; Table S3). WDR5 association with methyltrans-
ferases in the COMPASS complex leads to H3K4 methylation,
a validated marker of open-chromatin conformation and active
transcription (Steward et al., 2006; Trievel and Shilatifard, 2009;
Smith et al., 2011; Schuettengruber et al., 2011). We thus hy-
pothesized that knockdown of WDR5 would impact H3K4
methylation in PDAC cell lines. Using H3K4me3 chromatin
immunoprecipitation sequencing (ChIP-seq), we observed a
moderate overall reduction in global methylation levels in both
human and mouse PDAC cells (Figures S6F and S6G). Mapping
of tri-methylation profiles with functional elements of the
genome confirmed that a relatively small fraction (4%–20%)
of the methylation regions found altered upon WDR5 suppres-
sion was in proximity (<1 kb) of transcriptional start sites (TSSs)
(Figure S6H; Table S4). These results suggest that the COM-
PASS complexes may orchestrate the transcriptional control
of cancer-relevant genes that support PDAC maintenance.
We next performed cross-species RNA sequencing (RNA-
seq) analysis to inform on transcriptional changes consequent
to WDR5 knockdown (Figure 5F; Table S5). To our surprise,
gene set enrichment analysis (GSEA) identified genes involved
in the control of DNA replication and cell-cycle progression
(Figure 5G; Table S6).(F) Weight of the tumors (grams) harvested from Rosa26Cag-FlpoERT2/+; KRasG12D_L
for 1 week with tamoxifen (Tx, n = 7) or vehicle (Veh, n = 9) (Student’s t test p < 0
(G) Overall survival for somatic models in the KRasG12D_LSL/+; Tp53+/+; R26Cag-Flp
with Tamoxifen (Tx, n = 7) or vehicle (Veh, n = 5;Mantel-Cox test, p < 0.0005), or wit
(Veh, n = 5; Mantel-Cox test, n.s., not significant).
(H) Immunohistochemistry staining (WDR5, Ki67, phospho H2AX (gH2AX), 103)
KRasG12D_LSL/+; Tp53L/L background mice infected with pLSM5-K19-shWdr5 and
See also Figure S5.
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We next performed bromodeoxyuridine (BrdU)-labeling studies
in patient-derived PDAC cells and found that WDR5 knockdown
resulted in a reduction in BrdU incorporation, with a paradoxical
increase in overall DNA content, suggesting failure to sustain a
DNA replication checkpoint (Figures 6A and S7A–S7C). It is
well established that tumor cells are inherently more sensitive
to S-phase perturbations, possibly due to an increased number
of active replication forks and concomitant alterations in acti-
vating G1 checkpoints (Nghiem et al., 2001). Indeed, we found
that treatment with the ATR inhibitor, VE-821, caused accumula-
tion of replicative damage in the same human PDAC cell lines
(Figures 6B and S7D). In both cases, the observed dramatic
cell-cycle phenotype was associated with induction of DNA
damage (gH2AX staining) (Figures 6C, 6D, and S7E), which we
also observed upon knocking down WDR5 in vivo (Figure 4E).
Subcellular protein fractionation indicated a reduction of chro-
matin-bound CDC45 and an increase in chromatin-bound
CDT1 upon WDR5 knockdown, suggesting that prolonged stall-
ing of replication forks may underlie the observed arrest of the
replication machinery in the absence of WDR5 (Figure 6E). The
analysis of the chromatin-bound fraction also highlighted a
reduction in c-Myc as a consequence of WDR5 silencing. The
recent exciting finding of a direct interaction between WDR5
and c-Myc could imply thatWDR5may be recruited to chromatin
to execute on Myc-dependent functions in replication (Thomas
et al., 2015; Sun et al., 2015). By performing immunoprecipitation
experiments for exogenously expressed Flag-WDR5 or endoge-
nous c-Myc we confirmed the physical interaction of these two
proteins in PDAC cells (Figure 6F). Notably, WDR5 mutants car-
rying specific point mutations in the Myc binding site (L240K and
V268E; Thomas et al., 2015) drew accumulation of DNA damage
(gH2AX staining), similar to the effects seen upon knocking down
WDR5, and most likely due to dominant-negative effects on
PDAC cells (Figure 6G). The induction of DNA damage observed
upon infection of PDAC cells with these WDR5 mutants also re-
sulted in a significant impairment of new colony formation,
which was not detected when overexpressing wild-type WDR5
(Figure 6H). Finally, PDAC cells showed a greater sensitivity to
pharmacological inhibition of the WDR5 interaction network
(OICR-9429, 5–10 mM) than the specific inhibition of the
WDR5-MLL1 association (MM-401, 20–40 mM) in colony forma-
tion assays (Figure 6I).
DISCUSSION
Established cell lines and their transplanted tumors do not reflect
the heterogeneity of human cancer biology and have beenSL/+; Tp53L/L background mice infected with pLSM5-K19-shWdr5 and treated
.005).
oERT2/+ background infected with pLSM5-K19-shWdr5, and treated for 1 week
h pLSM5-K19-shNT and treated for 1 weekwith Tamoxifen (Tx, n = 5) or vehicle
of tumors collected (at the end of the treatments) from Rosa26Cag-FlpoERT2/+;
treated for 1 week with Tamoxifen (Tx) or vehicle (Veh).
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Figure 5. COMPASS Complex Subunits Are Required for PDAC Cell Proliferation
(A) Immunohistochemistry staining (WDR5, RBBP5, ASH2L, H3K4me3, 203) of PDAC xenografts.
(B and C) Western blot of RBBP5 and ASH2L for MDA-PATX53 cells expressing shRNA targeting RBBP5 (sh1 hRBBP5, sh2 hRBBP5), ASH2L (sh1 hASH2L, sh2
hASH2L), and control (sh NT) 72 hr after infection.
(D) Bar graph shows human MLL transcript levels in MDA-PATX53 cells infected with shRNA targeting MLL (sh1 hMLL, sh2 hMLL) or control (sh NT). Transcript
levels were quantified by RT-PCR 72 hr upon infection and expressed relative to mRNA levels in control (sh NT)-infected cells.
(legend continued on next page)
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adapted to growth in non-physiological culture conditions. Pri-
mary cancer patient-derived xenografts are indeed able to cap-
ture a broader set of tumor cell features compared to conven-
tional cancer cell lines, and they are being widely adopted to
test efficacy of novel candidate therapeutic agents (Tentler
et al., 2012). By focusing on targeting cell populations that can
adequately form tumors in vivo, we move the attention to those
cells required to survive upon transplantation and to sustain tu-
mor initiation and progression (Zhou et al., 2009; Viale et al.,
2014). We are aware that some of our top-scoring ‘‘hits’’ could
have been identified using cancer cell lines, as they may be
required for tumor cell proliferation, but so far no existing models
could have positioned them as unbiased lethal nodes for tumor
cells in a physiological context system. The stringency of our
approach allows us to focus solely on most promising ‘‘hits’’
on which we then can perform detailed clinical-pathological
and functional validation as illustrated in the case of WDR5.
Our results display a critical role of WDR5 in PDAC, seemingly
linked to sustaining a DNA replication checkpoint. Tumor cells
possess an increased number of replication forks and endure
elevated levels of replication stress compared to normal cells,
opening the intriguing possibility that WDR5 overexpression in
tumors may be required to stabilize the replication machinery
(Figure 7) (Gaillard et al., 2015). Our observations are particularly
intriguing considering the prominent role of ATR in S-phase
checkpoint activation and premature chromosome condensa-
tion (PCC) in the presence of replication-associated DNA dam-
age and absence of controlling G1 checkpoints (Nghiem et al.,
2001). Here, the confirmation of a direct and functional interac-
tion between WDR5 and c-Myc clearly demonstrated that
WDR5 is critical to recruit c-Myc on the chromatin and to enable
Myc-dependent tumorigenic mechanisms in PDAC (Dominguez-
Sola et al., 2007; Thomas et al., 2015). The role played by Myc in
transformation and cell-cycle regulation has been known for
many years, as well as its stabilization by oncogenic pathways
(Dang, 1999; Sears et al., 1999). In PDAC, where mutations of
Kras happen at a significantly high frequency, Myc is required
downstream of the MAPK cascade to sustain tumorigenesis (Is-
chenko et al., 2014; Stellas et al., 2014), and its knockdown in
Kras-driven pancreatic cells also reduced the expression of
metabolic genes critical for tumor maintenance (Ying et al.,
2012). The ability of Myc to promote cellular proliferation in
S-phase appears to occur through cooperation of effects,
some direct, e.g., those driving the regulation of nucleotide
biosynthetic pathways and the control of active replication forks,
others dependent on transcriptional activation, e.g., regulation of
cell-cycle genes (Campaner and Amati, 2012). In our experi-
ments, one of the Myc controlled mechanisms that emerge to
restrain replication stress is the ATR/Chk1 pathway (Murga
et al., 2011; Schoppy et al., 2012), which appears to support
rather than suppress tumor development. Whether this is a direct(E) Colony formation assay (CFA) for MDA-PATX53 cells expressing shRNA targe
hASH2L, middle panel), MLL (sh1 hMLL, sh2 hMLL, right panel), and control (sh
(F) Venn diagram of the genes differentially expressed in human and mouse PDA
(G) Gene set enrichment analysis (GSEA) of differentially expressed (DE) genes upo
two independent shRNA targeting WDR5 or control (sh NT) 72 hr after infection.
See also Figure S6 and Tables S3–S6.
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effect possibly mediated through Myc regulated genes by a
COMPASS or COMPASS-like complex, as demonstrated in neu-
roblastoma (Sun et al., 2015), cannot be determined from our
current studies. The findings of MLL being phosphorylated and
activated by ATR in order to allow for full activation of the
S-phase checkpoint further highlight the functional interplay be-
tween oncogene-induced DDR and COMPASS complex (Liu
et al., 2010). Our preliminary experiments with two available
low potency WDR5 inhibitors supported the centrality of the
WDR5 network (OICR-9429), more than MLL-specific associa-
tions (MM-401), in driving PDAC cell proliferation, but also high-
lighted the requirement for a new generation of potent and
selective Myc-oriented WDR5 inhibitors to deeply dissect the
WDR5-Myc molecular dynamics and accelerate the bench-to-
bedside translation process (Grebien et al., 2015; Cao et al.,
2014). In further support of our mechanistic findings, it was pre-
viously demonstrated that ATR inhibition sensitizes PDAC cell
lines to radiation or chemotherapy (Prevo et al., 2012).
Here, we also describe a highly efficient technology for
the rapid in vivo validation of any gene function in GEMM-
derived models of PDAC. Compared to the traditional validation
methods (constitutive or inducible RNAi tools), it has the advan-
tage of knocking down a gene of interest in a time-restricted
manner, in autochthonous pancreatic tumors originated from re-
programmed embryonic progenitors. It should be kept in mind
that this system has some intrinsic limitations, as the oncogene
activation (KrasG12D) and the inactivation of Tp53 are achieved in
E12.5/E13 liver progenitors, which, in spite of their remarkable
plasticity and their ability to expressmarkers of pancreatic termi-
nal differentiation upon transplantation, may still retain some fea-
tures of the embryonic tissue of origin and potentially generate
cholangiocarcinoma-like lesions.
Taken together, our data highlight this approach as a powerful
platform for the rapid identification of genetic vulnerabilities us-
ing patient-derived tumor samples. While here we chose to char-
acterize common hits across multiple tumors, the systematic
evaluation of epigenetic regulators in specific genetic contexts
and tumor molecular subtypes is certainly possible. This plat-
form can also be enabled in syngeneic mousemodels or human-
ized mice where one can probe the effects of target inhibition in
the context of an intact immune response and in the presence of
immune checkpoint activators.
EXPERIMENTAL PROCEDURES
Tumor Cell Isolation and Culture from Human PDx
Tumors from human primary xenografts (Xenograft I) were harvested in HBSS
(Gibco). Isolation of pancreatic adenocarcinoma tumor xenograft (PATX) cells
was performed by a combination of enzymatic (Tumor Dissociation Kit, hu-
man, Miltenyi Biotec) and mechanical (mincing the tumor tissue in very small
pieces with sterile scissors) dissociation protocols. The single-cell populationsting RBBP5 (sh1 hRBBP5, sh2 hRBBP5, left panel), ASH2L (sh1 hASH2L, sh2
NT).
C models upon WDR5 knockdown (RNA-seq replicates, FC >1.5, FDR 1%).
nWDR5 knockdown;Merge of the human andmouse PDAC cells infectedwith
Data are mean ± SD.
A B
C D
E
F
I
G
H
Figure 6. WDR5 Complex Protects PDAC Cells from Replicative Stress and DNA Damage through c-Myc
(A and B) DNA content analysis (DAPI) by flow cytometry for MDA-PATX53 cells infected with two independent shRNA targeting WDR5 (120 hr after infection) or
treated with ATR inhibitor VE-821 (0.5 and 1 mM, vehicle 0.1% DMSO) and collected 72 hr after drug addiction.
(C) Western blot for MDA-PATX53 cells expressing shRNA targeting WDR5 (sh1 hWDR5) and control (sh NT) at different time points after infection (48, 72, 96,
120 hr; NI, not infected); protein expression of phospho-H2AX (gH2AX), WDR5, and HSP90.
(D) Western blot for MDA-PATX53 cells treated for 72 hr with two different concentrations (0.5 and 1 mM) of the ATR inhibitor (VE-821) or vehicle (0.1% DMSO);
cells were harvested upon 1 hr treatment with (+) or without (–) Hydroxyurea (HU); protein expression of phospho-Chk1 (Ser345), phospho H2AX (gH2AX), and
Vinculin.
(E) Subcellular protein fractionation (cytoplasmic and chromatin-bound fractions) of MDA-PATX53 cells infected with two independent shRNA for WDR5 (Sh1
hWDR5, Sh2 hWDR5) or control (Sh NT) and collected 48 hr upon infection. Protein expression of CDC45, WDR5, CDT1, Myc, MCM2, and GAPDH.
(F) Immunoprecipitation (IP) of WDR5-Myc in MDA-PATX53 PDAC cells: whole-cell extracts (WCE, 0.5% input) collected from cells infected with pHAGE-2xFlag-
WDR5 or pHAGE-2xFlag-MBP (maltose-binding protein) (left panel); IP of the 2xFlag tag for the cells infected with pHAGE-2xFlag-WDR5 or pHAGE-2xFlag-MBP
(central panel, 1/15 of the eluates); IP of endogenous Myc for the cells infected with pHAGE-2xFlag-WDR5 or pHAGE-2xFlag-MBP (right panel, 1/15 of the
eluates), protein expression of WDR5, Flag, RBBP5, Myc, CDC45, and b-actin.
(legend continued on next page)
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Figure 7. WDR5 Is Critical to Sustain c-Myc Proliferative Functions in PDAC Cells
WDR5-Myc interaction regulates cell proliferation and DNA replication forks progression in normal non-tumorigenic cells or PDAC cells, through transcriptional
and non-transcriptional mechanisms. In PDAC, the presence of an activated oncogene (frequently Kras), driving c-Myc stabilization, and the absence of proficient
G1 checkpoint (p53 or p16 alterations) impose increased number of replication forks and elevated levels of replication stress compared to normal cells. In this
situation, disruption of the WDR5-Myc association sensitizes the pancreatic cancer cell to DNA damage accumulation and replication forks collapse.were seeded at high confluency on collagen-IV-coated plates (Corning) in
DMEM/F12 (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco),
1% BSA (Fisher Scientific), 0.5 mM hydrocortisone (Sigma-Aldrich), 10 mM
HEPES (Invitrogen), 100 ng/ml cholera toxin (Sigma-Aldrich), 5 ml/l insulin-
transferrin-selenium (BD), 100 IU/ml penicillin (Gibco), and 100 mg/ml strepto-
mycin (Gibco). In order to get rid of the murine fibroblasts in the culture, we
performed brief trypsinization cycles (0.25% Trypsin-EDTA, Gibco). The
enrichment for human components was confirmed by flow cytometry
comparing the percentage of cells expressing human (HLA-ABC) or mouse
(H-2Kd) histocompatibility complex antigens. The isolated human cells were
maintained in culture for a maximum of three passages before being trans-
planted in a secondary host (Xenograft II).
Libraries Design and Construction
A custom library constituted by 2,410 shRNAs focused on chromatin re-
modeling enzymes was constructed by using chip-based oligonucleotide
synthesis and cloned into the pRSI16 lentiviral vector (Cellecta) as a pool.
The shRNA library targeted 236 genes with coverage of 10 shRNAs/gene.
The shRNA includes two G/U mismatches in the passenger strand, a 7-nt
loop and a 21-nt targeting sequence. Targeting sequences were designed
using a proprietary algorithm (Cellecta). The oligo corresponding to each
shRNA was synthesized with a unique molecular barcode (18 nucleotides)
for measuring representation by NGS. The 12.5k barcoded library applied
for the engraftment efficiency studies was constructed using the same
technology and cloned as a pool into the pRSI17 lentiviral plasmid
(Cellecta).
In Vivo Engraftment Efficiency Studies
The volume of virus required to give a percentage of infection around 30% or
below was determined sample by samples using a three-point dose response(G andH)Western blot forMDA-PATX53 cells infectedwith different dilutions (1:40
site (L240K, V268E) and collected 48 hr after infection (NI, not infected), Protein ex
formation assay (CFA) of MDA-PATX53 cells expressing pHAGE-GFP, pHAGE-W
with 1:20 of the lentiviral preparation (lower panel).
(I) Colony formation assay (CFA) ofMDA-PATX53 cells in response to OICR-9429,
experiments as positive control, 10 nM). Numbers were normalized to colonies g
See also Figure S7.
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unit (TU)/cell for the human PDx cells; 0.3, 0.6, and 1.2 TU/cell for the GEMM-
derived cells (see Figure S2). Infectivity was determined as the percentage of
RFP positive cells 2 days after infection as measured by fluorescence-acti-
vated cell sorting (FACS) analysis. For large-scale infection of human PDx
and mouse GEMM-derived cells, 60 or 20 million cells were, respectively,
plated in T-175 flasks (Corning) with fresh media containing 8 mg/ml polybrene
and sufficient virus to guarantee a 15%–25% infection rate based on prece-
dent calculations. For each cell line, the optimal puromycin dose to achieve
more than 95% cell killing in 72 hr was determined by measuring cell viability
with a Cell Titer Glo assay (Promega) for a six-point dose response ranging
from 0 to 8 mg of puromycin. 72 hr following puromycin addiction, cells were
trypsinized, pooled together, and counted. A representative portion of the total
cells (normally one-third or one-fourth) was collected as reference cells and
immediately frozen as pellet at 80C. The cells for the in vivo studies were
separated into independent tubes (replicates or triplicates), suspended in
200 ml of a PBS:Matrigel (1:1) solution and injected subcutaneously into
the flank of 4- to 6-week-old female immunocompromised mice (NSG, The
Jackson Laboratory). The experiments with the GEMM-derived cells were
performed transplanting 106 cells permouse ensuring an in vivo representation
of 80 cells/barcode. For the human PDx experiments, each injection was
performed with 53 106 cells to guarantee an in vivo coverage of 400 cells/bar-
code. Specifically, the engraftment efficiency study with the MDA-PATX53 to
modulate the appropriate coveragewas executed in triplicate with 106, 33 106
and 5 3 106 cells from the same infection. Mice were monitored every 5 days
and euthanized when the tumors reached a volume around 750 mm3 as deter-
mined by caliper measurement. Tumor volume was calculated using the for-
mula: V = l2*L/2 (l, length; L, width). The whole tumor was collected from
each mouse under sterile conditions, weighed, and snap-frozen in liquid
nitrogen., 1:20, and 1:10) of pHAGE-WDR5wild-type (WT) ormutants in theMyc-binding
pression of phospho-H2AX (gH2AX), WDR5 and Vinculin (upper panel); colony
DR5 wild-type (WT) or pHAGE-WDR5 mutants (L240K, V268E) upon infection
MM-401, and VE-821 at indicated concentrations (Taxol has been used in these
enerated in response to 0.1% DMSO (vehicle). Data are mean ± SD.
In Vivo shRNA Screens
Infectivity was determined sample by sample as the percentage of GFP positive
cells 2 days after infection asmeasured by FACS analysis. For large-scale infec-
tion of human PDx andmouse GEMM-derived cells the same experimental pro-
cedure described above has been applied (see In Vivo Engraftment Efficiency
Studies). The experiments with the GEMM-derived cells were performed trans-
planting 106 cells per mouse ensuring an in vivo representation of 400 cells/bar-
code. For the human PDx experiments, each injection was performed with 5 3
106 cells to guarantee an in vivo coverage of 2,000 cells/barcode.
Bioinformatics and Data Analysis
Read Counting
Illumina base calls were processed using CASAVA (v.1.8.2), and resulting
reads were processed using our in-house pipeline. Raw FASTQ files are
filtered for a 4-bp spacer (CGAA) starting at 18th base allowing for one
mismatch, such that only reads amplified using above mentioned PCRs are
used for further processing. We then extract 23–40 bp of the above reads
for targeting libraries, and 1–18 bp for non-targeting library. These are further
aligned using Bowtie (2.0.2) to their respective libraries (2.4k mouse Epige-
nome, 2.4k human Epigenome, and 12.5k non-targeting library) (Langmead
et al., 2009). We then use SAMtools to count the number of reads aligned to
each barcode (Li et al., 2009).
Engraftment Efficiency Analysis
Read counts are normalized for the amount of sequencing reads retrieved for
each sample, using library size normalization (to 100 million reads).
Screen Hit Analysis
A similar approach was employed as with engraftment efficiency analysis,
described above. Using normalized counts, each sample is compared with its
respective reference and a Log2 fold change (FC) is calculated. This is further
normalized using a robust Z score defined by (FC – Median)/Median absolute
deviation (MAD) (Ko¨nig et al., 2007). To summarize the effect of knockdown at
gene level we employed RSA, to score each gene (Birmingham et al., 2009).
Somatic Lentiviral Vectors and Other Plasmids
pLSM5: a synthetic cassette (Geneart, Life Technologies) containing the U6
promoter and the Cre recombinase sequence under the human Keratin 19 pro-
moter (1114, +141) flanked by two TATA-Frt sites (XbaI-U6-TATA-Frt-EcoRI-
hKrt19-NheI-Cre-TATA-Frt-HpaI) was cloned into the XbaI/HpaI site of the
pSICO vector. A DNA fragment was liberated by XbaI/KpnI digestion and
cloned into the XbaI/KpnI sites of the pLB vector 32. The introduction of the
TATA box into the Frt sites was designed according to Ventura et al. (2004).
All the constructs were verified by restriction digestion and sequencing. The
pSICO and pSICO-Flpo were made by Dr. Tyler Jacks (Ventura et al., 2007).
The pLB vector was created by Dr. Stephan Kissler. All plasmids were ob-
tained through Addgene.
Lentiviral Somatic Mosaic GEM Model
Embryonic liver progenitors (E12.5/E13) were isolated and cultured according
to Zender et al. (2008). Cells were infected 24 hr after seeding with the pLSM5
virus, and 2 3 105 cells were injected in the tail of the pancreas of Rag2/
mice. Before cell injection, Rag2/ mice, approximately 8–10 weeks old,
received seven consecutive (one each day) intraperitoneal injections of ceru-
lein (10 mg/kg) according to Morris et al. (2010). Animals were monitored
weekly for tumor formation. Tumor-bearing mice were injected intraperitone-
ally every other day with Tamoxifen (5 3 100-ml injections, 15 mg/ml).
ACCESSION NUMBERS
The accession number for the RNA-seq and ChIP-seq data reported in this pa-
per is European Genome-Phenome Archive (EGA): PRJEB13892.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and six tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.05.063.AUTHOR CONTRIBUTIONS
Conceptualization, A.C., G.G., S.S., T.P.H., L.L., and G.F.D.; Methodology,
A.C., G.G., S.S., D.B., and A.C.; Software, S.S., P.K.S., K.C.A., C.A.B., and
L.R.; Investigation, A.C., G.G., L.N., J.L.R., A.C., D.B., A.V., P.F.P., F.S.R.,
J.T., N.S., S.G., M.R.E., V.G., G.I.D., W.Y., T.G., C.D., and D.C.; Writing – Orig-
inal Draft, A.C., G.F.D., and T.P.H.; Writing – Review & Editing, P.G.P., L.C.,
and R.A.D.; Resources, M.E.D., Y.K., P.J., H.W., J.B.F., and A.M.; Funding
Acquisition, T.P.H., A.V., and G.F.D.; Supervision: L.L. and G.F.D.
ACKNOWLEDGMENTS
We thank Dr. Simona Colla, Dr. Carlo Toniatti, Dr. Saverio Minucci, Dr. Angela
Deem, and Dr. Matteo Marchesini for discussion and suggestions. We thank
Dr. Alessia Petrocchi, Trang Tieu, and Michael Peoples for providing reagents.
We wish to thank all the members of G.F.D.’s, R.A.D.’s, and L.C.’s labs for dis-
cussion and reagents. We thank the UTMDACC Sequencing and Microarray
Facility (SMF), the UTMDACC Flow Cytometry and Cellular Imaging Core Fa-
cility (NCI Cancer Center Support Grant P30CA16672), the UTMDACCDepart-
ment of Veterinary Medicine, and the UTMDACC Small Animal Imaging Facil-
ity. This research was supported by the AACR 14-90-25 grant to G.F.D. and
grants from the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic
Cancer to G.F.D., A.V., and T.P.H. A.C. was recipient of a fellowship from
the Italian Foundation for Cancer Research (FIRC).
Received: December 11, 2015
Revised: March 21, 2016
Accepted: May 16, 2016
Published: June 16, 2016
REFERENCES
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho,
M. (1988). Most human carcinomas of the exocrine pancreas contain mutant
c-K-ras genes. Cell 53, 549–554.
American Cancer Society. (2015). Cancer Facts & Figures.
Baratta, M.G., Schinzel, A.C., Zwang, Y., Bandopadhayay, P., Bowman-Colin,
C., Kutt, J., Curtis, J., Piao, H., Wong, L.C., Kung, A.L., et al. (2015). An in-tu-
mor genetic screen reveals that the BET bromodomain protein, BRD4, is a po-
tential therapeutic target in ovarian carcinoma. Proc. Natl. Acad. Sci. USA 112,
232–237.
Biankin, A.V., Waddell, N., Kassahn, K.S., Gingras, M.C., Muthuswamy, L.B.,
Johns, A.L., Miller, D.K., Wilson, P.J., Patch, A.M., Wu, J., et al.; Australian
Pancreatic Cancer Genome Initiative (2012). Pancreatic cancer genomes
reveal aberrations in axon guidance pathway genes. Nature 491, 399–405.
Birmingham, A., Selfors, L.M., Forster, T., Wrobel, D., Kennedy, C.J., Shanks,
E., Santoyo-Lopez, J., Dunican, D.J., Long, A., Kelleher, D., et al. (2009). Sta-
tistical methods for analysis of high-throughput RNA interference screens. Nat.
Methods 6, 569–575.
Bonnefoix, T., and Callanan, M. (2010). Revisiting the concept of phenotypi-
cally distinct malignant pancreatic stem-cell subsets based on limiting dilution
transplantation assays. J. Clin. Oncol. 28, e89–e90.
Campaner, S., and Amati, B. (2012). Two sides of the Myc-induced DNA dam-
age response: from tumor suppression to tumor maintenance. Cell Div. 7, 6.
Cao, F., Townsend, E.C., Karatas, H., Xu, J., Li, L., Lee, S., Liu, L., Chen, Y.,
Ouillette, P., Zhu, J., et al. (2014). Targeting MLL1 H3K4 methyltransferase ac-
tivity in mixed-lineage leukemia. Mol. Cell 53, 247–261.
Chen, X., Xie, W., Gu, P., Cai, Q., Wang, B., Xie, Y., Dong, W., He, W., Zhong,
G., Lin, T., and Huang, J. (2015). Upregulated WDR5 promotes proliferation,
self-renewal and chemoresistance in bladder cancer via mediating H3K4 tri-
methylation. Sci. Rep. 5, 8293.
Conroy, T., Desseigne, F., Ychou, M., Bouche´, O., Guimbaud, R., Be´couarn,
Y., Adenis, A., Raoul, J.L., Gourgou-Bourgade, S., de la Fouchardie`re, C.,
et al.; Groupe Tumeurs Digestives of Unicancer; PRODIGE IntergroupCell Reports 16, 133–147, June 28, 2016 145
(2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
N. Engl. J. Med. 364, 1817–1825.
Dang, C.V. (1999). c-Myc target genes involved in cell growth, apoptosis, and
metabolism. Mol. Cell. Biol. 19, 1–11.
Dawson, M.A., and Kouzarides, T. (2012). Cancer epigenetics: from mecha-
nism to therapy. Cell 150, 12–27.
Dominguez-Sola, D., Ying, C.Y., Grandori, C., Ruggiero, L., Chen, B., Li, M.,
Galloway, D.A., Gu, W., Gautier, J., and Dalla-Favera, R. (2007). Non-tran-
scriptional control of DNA replication by c-Myc. Nature 448, 445–451.
Gaillard, H., Garcı´a-Muse, T., and Aguilera, A. (2015). Replication stress and
cancer. Nat. Rev. Cancer 15, 276–289.
Grebien, F., Vedadi, M., Getlik, M., Giambruno, R., Grover, A., Avellino, R.,
Skucha, A., Vittori, S., Kuznetsova, E., Smil, D., et al. (2015). Pharmacological
targeting of the Wdr5-MLL interaction in C/EBPa N-terminal leukemia. Nat.
Chem. Biol. 11, 571–578.
Hingorani, S.R., Petricoin, E.F., Maitra, A., Rajapakse, V., King, C., Jacobetz,
M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A., et al. (2003). Preinva-
sive and invasive ductal pancreatic cancer and its early detection in themouse.
Cancer Cell 4, 437–450.
Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban,
R.H., Rustgi, A.K., Chang, S., and Tuveson, D.A. (2005). Trp53R172H and
KrasG12D cooperate to promote chromosomal instability and widely metastatic
pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469–483.
Hoffman, G.R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bag-
dasarian, L., Huber, J., Lindeman, A., Chen, D., et al. (2014). Functional epige-
netics approach identifies BRM/SMARCA2 as a critical synthetic lethal target
in BRG1-deficient cancers. Proc. Natl. Acad. Sci. USA 111, 3128–3133.
Hu, Y., and Smyth, G.K. (2009). ELDA: extreme limiting dilution analysis for
comparing depleted and enriched populations in stem cell and other assays.
J. Immunol. Methods 347, 70–78.
Hubert, C.G., Bradley, R.K., Ding, Y., Toledo, C.M., Herman, J., Skutt-Kakaria,
K., Girard, E.J., Davison, J., Berndt, J., Corrin, P., et al. (2013). Genome-wide
RNAi screens in human brain tumor isolates reveal a novel viability requirement
for PHF5A. Genes Dev. 27, 1032–1045.
Ischenko, I., Petrenko, O., and Hayman, M.J. (2014). Analysis of the tumor-
initiating and metastatic capacity of PDX1-positive cells from the adult
pancreas. Proc. Natl. Acad. Sci. USA 111, 3466–3471.
Ishizawa, K., Rasheed, Z.A., Karisch, R., Wang, Q., Kowalski, J., Susky, E.,
Pereira, K., Karamboulas, C., Moghal, N., Rajeshkumar, N.V., et al. (2010). Tu-
mor-initiating cells are rare in many human tumors. Cell Stem Cell 7, 279–282.
Kim, J.Y., Banerjee, T., Vinckevicius, A., Luo, Q., Parker, J.B., Baker, M.R.,
Radhakrishnan, I., Wei, J.J., Barish, G.D., and Chakravarti, D. (2014). A role
for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation
on histone H3 during androgen signaling and in prostate cancer. Mol. Cell
54, 613–625.
Ko¨nig, R., Chiang, C.Y., Tu, B.P., Yan, S.F., DeJesus, P.D., Romero, A., Ber-
gauer, T., Orth, A., Krueger, U., Zhou, Y., and Chanda, S.K. (2007). A probabil-
ity-based approach for the analysis of large-scale RNAi screens. Nat. Methods
4, 847–849.
Krattenmacher, A., et al. (2014). Synthetic lethality screen identifies SMC2 as a
new target gene in pancreatic cancer. Pancreatology 13, S66.
Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009). Ultrafast and
memory-efficient alignment of short DNA sequences to the human genome.
Genome Biol. 10, R25.
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G.,
Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing Sub-
group (2009). The Sequence alignment/map (SAM) format and SAMtools. Bio-
informatics 25, 2078–2079.
Liu, H., Takeda, S., Kumar, R., Westergard, T.D., Brown, E.J., Pandita, T.K.,
Cheng, E.H., andHsieh, J.J. (2010). Phosphorylation ofMLL by ATR is required
for execution of mammalian S-phase checkpoint. Nature 467, 343–346.146 Cell Reports 16, 133–147, June 28, 2016Meacham, C.E., Ho, E.E., Dubrovsky, E., Gertler, F.B., and Hemann, M.T.
(2009). In vivo RNAi screening identifies regulators of actin dynamics as key
determinants of lymphoma progression. Nat. Genet. 41, 1133–1137.
Moffat, J., Grueneberg, D.A., Yang, X., Kim, S.Y., Kloepfer, A.M., Hinkle, G.,
Piqani, B., Eisenhaure, T.M., Luo, B., Grenier, J.K., et al. (2006). A lentiviral
RNAi library for human and mouse genes applied to an arrayed viral high-con-
tent screen. Cell 124, 1283–1298.
Morris, J.P., 4th, Cano, D.A., Sekine, S., Wang, S.C., and Hebrok, M. (2010).
Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic
cancer precursor lesions in mice. J. Clin. Invest. 120, 508–520.
Murga, M., Campaner, S., Lopez-Contreras, A.J., Toledo, L.I., Soria, R., Mon-
tan˜a, M.F., D’Artista, L., Schleker, T., Guerra, C., Garcia, E., et al. (2011). Ex-
ploiting oncogene-induced replicative stress for the selective killing of Myc-
driven tumors. Nat. Struct. Mol. Biol. 18, 1331–1335.
Nghiem, P., Park, P.K., Kim, Y., Vaziri, C., and Schreiber, S.L. (2001). ATR in-
hibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature
chromatin condensation. Proc. Natl. Acad. Sci. USA 98, 9092–9097.
Omura, N., and Goggins, M. (2009). Epigenetics and epigenetic alterations in
pancreatic cancer. Int. J. Clin. Exp. Pathol. 2, 310–326.
Possemato, R., Marks, K.M., Shaul, Y.D., Pacold, M.E., Kim, D., Birsoy, K., Se-
thumadhavan, S.,Woo, H.K., Jang, H.G., Jha, A.K., et al. (2011). Functional ge-
nomics reveal that the serine synthesis pathway is essential in breast cancer.
Nature 476, 346–350.
Possik, P.A., M€uller, J., Gerlach, C., Kenski, J.C., Huang, X., Shahrabi, A.,
Krijgsman, O., Song, J.Y., Smit, M.A., Gerritsen, B., et al. (2014). Parallel in vivo
and in vitromelanoma RNAi dropout screens reveal synthetic lethality between
hypoxia and DNA damage response inhibition. Cell Rep. 9, 1375–1386.
Prevo, R., Fokas, E., Reaper, P.M., Charlton, P.A., Pollard, J.R., McKenna,
W.G., Muschel, R.J., and Brunner, T.B. (2012). The novel ATR inhibitor VE-
821 increases sensitivity of pancreatic cancer cells to radiation and chemo-
therapy. Cancer Biol. Ther. 13, 1072–1081.
Quintana, E., Shackleton, M., Sabel, M.S., Fullen, D.R., Johnson, T.M., and
Morrison, S.J. (2008). Efficient tumour formation by single human melanoma
cells. Nature 456, 593–598.
Sahai, V., Kumar, K., Knab, L.M., Chow, C.R., Raza, S.S., Bentrem, D.J.,
Ebine, K., and Munshi, H.G. (2014). BET bromodomain inhibitors block growth
of pancreatic cancer cells in three-dimensional collagen. Mol. Cancer Ther. 13,
1907–1917.
Schlabach, M.R., Luo, J., Solimini, N.L., Hu, G., Xu, Q., Li, M.Z., Zhao, Z., Smo-
gorzewska, A., Sowa, M.E., Ang, X.L., et al. (2008). Cancer proliferation gene
discovery through functional genomics. Science 319, 620–624.
Scholl, C., Fro¨hling, S., Dunn, I.F., Schinzel, A.C., Barbie, D.A., Kim, S.Y., Sil-
ver, S.J., Tamayo, P., Wadlow, R.C., Ramaswamy, S., et al. (2009). Synthetic
lethal interaction between oncogenic KRAS dependency and STK33 suppres-
sion in human cancer cells. Cell 137, 821–834.
Schoppy, D.W., Ragland, R.L., Gilad, O., Shastri, N., Peters, A.A., Murga, M.,
Fernandez-Capetillo, O., Diehl, J.A., and Brown, E.J. (2012). Oncogenic stress
sensitizes murine cancers to hypomorphic suppression of ATR. J. Clin. Invest.
122, 241–252.
Schuettengruber, B., Martinez, A.M., Iovino, N., and Cavalli, G. (2011). Tri-
thorax group proteins: switching genes on and keeping them active. Nat.
Rev. Mol. Cell Biol. 12, 799–814.
Sears, R., Leone, G., DeGregori, J., and Nevins, J.R. (1999). Ras enhances
Myc protein stability. Mol. Cell 3, 169–179.
Silva, J.M., Marran, K., Parker, J.S., Silva, J., Golding, M., Schlabach,M.R., El-
ledge, S.J., Hannon, G.J., andChang, K. (2008). Profiling essential genes in hu-
man mammary cells by multiplex RNAi screening. Science 319, 617–620.
Smith, E., Lin, C., and Shilatifard, A. (2011). The super elongation complex
(SEC) and MLL in development and disease. Genes Dev. 25, 661–672.
Stathis, A., and Moore, M.J. (2010). Advanced pancreatic carcinoma: current
treatment and future challenges. Nat. Rev. Clin. Oncol. 7, 163–172.
Stellas, D., Szabolcs, M., Koul, S., Li, Z., Polyzos, A., Anagnostopoulos, C.,
Cournia, Z., Tamvakopoulos, C., Klinakis, A., and Efstratiadis, A. (2014).
Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J. Natl.
Cancer Inst. 106, dju320.
Steward, M.M., Lee, J.S., O’Donovan, A., Wyatt, M., Bernstein, B.E., and Shi-
latifard, A. (2006). Molecular regulation of H3K4 trimethylation by ASH2L, a
shared subunit of MLL complexes. Nat. Struct. Mol. Biol. 13, 852–854.
Sun, Y., Bell, J.L., Carter, D., Gherardi, S., Poulos, R.C., Milazzo, G., Wong,
J.W., Al-Awar, R., Tee, A.E., Liu, P.Y., et al. (2015). WDR5 supports an
N-Myc transcriptional complex that drives a protumorigenic gene expression
signature in neuroblastoma. Cancer Res. 75, 5143–5154.
Tentler, J.J., Tan, A.C., Weekes, C.D., Jimeno, A., Leong, S., Pitts, T.M., Arcar-
oli, J.J., Messersmith, W.A., and Eckhardt, S.G. (2012). Patient-derived tumour
xenografts asmodels for oncology drug development. Nat. Rev. Clin. Oncol. 9,
338–350.
Thomas, L.R., Wang, Q., Grieb, B.C., Phan, J., Foshage, A.M., Sun, Q., Olej-
niczak, E.T., Clark, T., Dey, S., Lorey, S., et al. (2015). Interaction with WDR5
promotes target gene recognition and tumorigenesis by MYC. Mol. Cell 58,
440–452.
Trievel, R.C., and Shilatifard, A. (2009). WDR5, a complexed protein. Nat.
Struct. Mol. Biol. 16, 678–680.
Ventura, A., Meissner, A., Dillon, C.P., McManus, M., Sharp, P.A., Van Parijs,
L., Jaenisch, R., and Jacks, T. (2004). Cre-lox-regulated conditional RNA inter-
ference from transgenes. Proc. Natl. Acad. Sci. USA 101, 10380–10385.
Ventura, A., Kirsch, D.G., McLaughlin, M.E., Tuveson, D.A., Grimm, J., Lintault,
L., Newman, J., Reczek, E.E., Weissleder, R., and Jacks, T. (2007). Restoration
of p53 function leads to tumour regression in vivo. Nature 445, 661–665.
Viale, A., Pettazzoni, P., Lyssiotis, C.A., Ying, H., Sa´nchez, N., Marchesini, M.,
Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014). Oncogene ablation-
resistant pancreatic cancer cells depend on mitochondrial function. Nature
514, 628–632.Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M.,
Seay, T., Tjulandin, S.A., Ma, W.W., Saleh, M.N., et al. (2013). Increased sur-
vival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J.
Med. 369, 1691–1703.
Waddell, N., Pajic, M., Patch, A.M., Chang, D.K., Kassahn, K.S., Bailey, P.,
Johns, A.L., Miller, D., Nones, K., Quek, K., et al.; Australian Pancreatic Cancer
Genome Initiative (2015). Whole genomes redefine the mutational landscape
of pancreatic cancer. Nature 518, 495–501.
Wang, P., Lin, C., Smith, E.R., Guo, H., Sanderson, B.W., Wu, M., Gogol, M.,
Alexander, T., Seidel, C., Wiedemann, L.M., et al. (2009). Global analysis of
H3K4 methylation defines MLL family member targets and points to a role
for MLL1-mediated H3K4 methylation in the regulation of transcriptional initi-
ation by RNA polymerase II. Mol. Cell. Biol. 29, 6074–6085.
Ying, H., Kimmelman, A.C., Lyssiotis, C.A., Hua, S., Chu, G.C., Fletcher-San-
anikone, E., Locasale, J.W., Son, J., Zhang, H., Coloff, J.L., et al. (2012). Onco-
genic Krasmaintains pancreatic tumors through regulation of anabolic glucose
metabolism. Cell 149, 656–670.
Yu, B.D., Hess, J.L., Horning, S.E., Brown, G.A., and Korsmeyer, S.J. (1995).
Altered Hox expression and segmental identity in Mll-mutant mice. Nature
378, 505–508.
Zender, L., Xue, W., Zuber, J., Semighini, C.P., Krasnitz, A., Ma, B., Zender, P.,
Kubicka, S., Luk, J.M., Schirmacher, P., et al. (2008). An oncogenomics-based
in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135,
852–864.
Zhou, B.B., Zhang, H., Damelin, M., Geles, K.G., Grindley, J.C., and Dirks, P.B.
(2009). Tumour-initiating cells: challenges and opportunities for anticancer
drug discovery. Nat. Rev. Drug Discov. 8, 806–823.Cell Reports 16, 133–147, June 28, 2016 147
